These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Gender Differences in Psycho-Social-Spiritual Healing. Luna MJ; Ameli R; Sinaii N; Cheringal J; Panahi S; Berger A J Womens Health (Larchmt); 2019 Nov; 28(11):1513-1521. PubMed ID: 31502927 [No Abstract] [Full Text] [Related]
3. Single-Dose Synthetic Psilocybin With Psychotherapy for Treatment-Resistant Bipolar Type II Major Depressive Episodes: A Nonrandomized Open-Label Trial. Aaronson ST; van der Vaart A; Miller T; LaPratt J; Swartz K; Shoultz A; Lauterbach M; Sackeim HA; Suppes T JAMA Psychiatry; 2024 Jun; 81(6):555-562. PubMed ID: 38055270 [TBL] [Abstract][Full Text] [Related]
4. Effects of Psilocybin-Assisted Therapy on Major Depressive Disorder: A Randomized Clinical Trial. Davis AK; Barrett FS; May DG; Cosimano MP; Sepeda ND; Johnson MW; Finan PH; Griffiths RR JAMA Psychiatry; 2021 May; 78(5):481-489. PubMed ID: 33146667 [TBL] [Abstract][Full Text] [Related]
5. Cross Cultural Adaptation and Cognitive Testing of a Psycho-Social-Spiritual Healing Measure, the NIH Healing Experiences in All Life Stressors-NIH-HEALS. Namisango E; Luyirika EBK; Berger A Glob Adv Health Med; 2022; 11():21649561211067189. PubMed ID: 35096489 [TBL] [Abstract][Full Text] [Related]
6. Psilocybin-assisted therapy for major depressive disorder: An exploratory placebo-controlled, fixed-order trial. Sloshower J; Skosnik PD; Safi-Aghdam H; Pathania S; Syed S; Pittman B; D'Souza DC J Psychopharmacol; 2023 Jul; 37(7):698-706. PubMed ID: 36938991 [TBL] [Abstract][Full Text] [Related]
7. Psilocybin-assisted psychotherapy for depression: Emerging research on a psychedelic compound with a rich history. Pearson C; Siegel J; Gold JA J Neurol Sci; 2022 Mar; 434():120096. PubMed ID: 34942586 [TBL] [Abstract][Full Text] [Related]
8. Trial of Psilocybin versus Escitalopram for Depression. Carhart-Harris R; Giribaldi B; Watts R; Baker-Jones M; Murphy-Beiner A; Murphy R; Martell J; Blemings A; Erritzoe D; Nutt DJ N Engl J Med; 2021 Apr; 384(15):1402-1411. PubMed ID: 33852780 [TBL] [Abstract][Full Text] [Related]
9. HOPE: A Pilot Study of Psilocybin Enhanced Group Psychotherapy in Patients With Cancer. Lewis BR; Garland EL; Byrne K; Durns T; Hendrick J; Beck A; Thielking P J Pain Symptom Manage; 2023 Sep; 66(3):258-269. PubMed ID: 37302533 [TBL] [Abstract][Full Text] [Related]
10. Psilocybin-assisted therapy for depression: A systematic review and meta-analysis. Haikazian S; Chen-Li DCJ; Johnson DE; Fancy F; Levinta A; Husain MI; Mansur RB; McIntyre RS; Rosenblat JD Psychiatry Res; 2023 Nov; 329():115531. PubMed ID: 37844352 [TBL] [Abstract][Full Text] [Related]
11. The Therapeutic Potential of Psilocybin. Lowe H; Toyang N; Steele B; Valentine H; Grant J; Ali A; Ngwa W; Gordon L Molecules; 2021 May; 26(10):. PubMed ID: 34063505 [TBL] [Abstract][Full Text] [Related]
12. Psilocybin-assisted group therapy in patients with cancer diagnosed with a major depressive disorder. Agrawal M; Richards W; Beaussant Y; Shnayder S; Ameli R; Roddy K; Stevens N; Richards B; Schor N; Honstein H; Jenkins B; Bates M; Thambi P Cancer; 2024 Apr; 130(7):1137-1146. PubMed ID: 38105655 [TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of psilocybin-assisted treatment for major depressive disorder: Prospective 12-month follow-up. Gukasyan N; Davis AK; Barrett FS; Cosimano MP; Sepeda ND; Johnson MW; Griffiths RR J Psychopharmacol; 2022 Feb; 36(2):151-158. PubMed ID: 35166158 [TBL] [Abstract][Full Text] [Related]
14. Sub-acute effects of psilocybin on EEG correlates of neural plasticity in major depression: Relationship to symptoms. Skosnik PD; Sloshower J; Safi-Aghdam H; Pathania S; Syed S; Pittman B; D'Souza DC J Psychopharmacol; 2023 Jul; 37(7):687-697. PubMed ID: 37392016 [TBL] [Abstract][Full Text] [Related]
15. The Watts Connectedness Scale: a new scale for measuring a sense of connectedness to self, others, and world. Watts R; Kettner H; Geerts D; Gandy S; Kartner L; Mertens L; Timmermann C; Nour MM; Kaelen M; Nutt D; Carhart-Harris R; Roseman L Psychopharmacology (Berl); 2022 Nov; 239(11):3461-3483. PubMed ID: 35939083 [TBL] [Abstract][Full Text] [Related]
16. Long-term follow-up of psilocybin-assisted psychotherapy for psychiatric and existential distress in patients with life-threatening cancer. Agin-Liebes GI; Malone T; Yalch MM; Mennenga SE; Ponté KL; Guss J; Bossis AP; Grigsby J; Fischer S; Ross S J Psychopharmacol; 2020 Feb; 34(2):155-166. PubMed ID: 31916890 [TBL] [Abstract][Full Text] [Related]
17. Acceptability of psilocybin-assisted group therapy in patients with cancer and major depressive disorder: Qualitative analysis. Beaussant Y; Tarbi E; Nigam K; Miner S; Sager Z; Sanders JJ; Ljuslin M; Guérin B; Thambi P; Tulsky JA; Agrawal M Cancer; 2024 Apr; 130(7):1147-1157. PubMed ID: 38105653 [TBL] [Abstract][Full Text] [Related]
18. Psilocybin for the Treatment of Depression: A Promising New Pharmacotherapy Approach. Agin-Liebes G; Davis AK Curr Top Behav Neurosci; 2022; 56():125-140. PubMed ID: 34811715 [TBL] [Abstract][Full Text] [Related]
19. Psilocybin with psychological support for treatment-resistant depression: six-month follow-up. Carhart-Harris RL; Bolstridge M; Day CMJ; Rucker J; Watts R; Erritzoe DE; Kaelen M; Giribaldi B; Bloomfield M; Pilling S; Rickard JA; Forbes B; Feilding A; Taylor D; Curran HV; Nutt DJ Psychopharmacology (Berl); 2018 Feb; 235(2):399-408. PubMed ID: 29119217 [TBL] [Abstract][Full Text] [Related]